← The Wire
APGENasdaq
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · CIK 1974640
Apogee Therapeutics develops and researches programs, incurring significant operating losses
red 8-K · 90d🔥 High media attention
$6.66B
Market cap
$132.61
Last close
+0.1%
1D
+0.1%
5D
3.5M
Volume
Price · last 39 sessions+58.7%
May 4L $77.75 · H $132.88Jun 29
79
Total filings
Jun 26, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFA 14AJun 26, 2026DEFA14ADEFA 14AJun 22, 2026DEFA14ADEFA14AJun 22, 2026DEFA14ADEFA14AApr 24, 2026DEFA14ADEFA14AApr 29, 2025DEFA14ADEFA14AMay 28, 2024DEFA14ADEFA14AApr 24, 2024
Insider Activity
In the 90 days to Mar 25, 2026: 4 sold $141.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Henderson JaneChief Financial Officer | Sell | 2,000 | $85.00 | $170K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 8,363 | $74.29 | $621K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 8,219 | $74.83 | $615K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 3,418 | $75.86 | $259K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 3,225 | $70.33 | $227K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 2,075 | $71.98 | $149K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 200 | $73.26 | $15K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 994 | $70.45 | $70K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 406 | $71.66 | $29K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 300 | $69.43 | $21K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 300 | $68.27 | $20K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 11,494 | $62.96 | $724K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 7,551 | $63.73 | $481K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 955 | $64.99 | $62K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 2,481 | $64.88 | $161K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 1,420 | $65.83 | $93K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 1,299 | $66.85 | $87K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 200 | $68.94 | $14K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 100 | $67.88 | $7K |
| Feb 2, 2026 | Henderson JaneChief Financial Officer | Sell | 1,108 | $66.15 | $73K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 7 reputable articles.
Investor's Business DailyAbbVie Goes On The Offensive With $10.9 Billion Takeover7d agoBarron'sWhy AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising7d agoReutersAbbVie sharpens immunology focus with $10.9 billion Apogee deal7d agoBloomberg.comAbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash7d agoCNBCStocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more8d agoBarron'sS&P 500 Futures Fall in Premarket Trading; Apogee Therapeutics, Fervo Energy Lead8d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance